Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention

Psychiatry Research

Volumn 249, Issue , 2017, Pages 318-320

  Sherman, Brian J ^a   Baker, Nathaniel L ^a   McRae Clark, Aimee L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cannabis; Oxytocin; Treatment

Indexed keywords

OXYTOCIN; PLACEBO; CANNABIS; OXYTOCIC AGENT;

ADULT; ARTICLE; BEHAVIOR CHANGE; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MOTIVATIONAL ENHANCEMENT THERAPY; OUTCOME ASSESSMENT; PILOT STUDY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CANNABIS SMOKING; MARIJUANA ABUSE; MOTIVATIONAL INTERVIEWING; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CANNABIS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MOTIVATIONAL INTERVIEWING; OXYTOCICS; OXYTOCIN; PILOT PROJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85012294020     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2017.01.027     Document Type: Article

References (23)

1. Brown, H., Prescott, R., Applied Mixed Models in Medicine. 1999, John Wiley & Sons, New York.
2. Butovsky, E., Juknat, A., Elbaz, J., Shabat-Simon, M., Eilam, R., Zangen, A., et al. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol. Cell Neurosci. 31:4 (2006), 795–804.
3. Cardoso, C., Ellenbogen, M.A., Linnen, A.M., Acute intranasal oxytocin improves positive self- perceptions of personality. Psychopharmacol. (Berl.) 220:4 (2012), 741–749.
4. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCIP-I/P, version 2.0). 1996, Biometrics Department, New York State Psychiatric Institute, New York.
5. Hasin, D.S., Kerridge, B.T., Saha, T.D., Huang, B., Pickering, R., Smith, S.M., et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the National Epidemiologic Survey on Alcohol And Related Conditions-III. Am. J. Psychiatry 173:6 (2016), 588–599.
6. Heinrichs, M., Baumgartner, T., Kirschbaum, C., Ehlert, U., Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol. Psychiatry 54:12 (2003), 1389–1398.
7. Kosfeld, M., Heinrichs, M., Zak, P.J., Fischbacher, U., Fehr, E., Oxytocin increases trust in humans. Nature 435 (2005), 673–676.
8. Lee, M.R., Rohn, M.C., Tanda, G., Leggio, L., et al. Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs 30:2 (2016), 109–123.
9. Marijuana Treatment Project Research Group, Brief treatments for cannabis dependence: findings from a randomized multisite trial. J. Consult Clin. Psychol. 72:3 (2004), 455–466.
10. McGregor, I.S., Bowen, M.T., Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm. Behav. 61:3 (2012), 331–339.
11. McRae-Clark, A.L., Baker, N.L., Maria, M.M., Brady, K.T., Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacol. (Berl.) 228:4 (2013), 623–631.
12. Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M., Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12:9 (2011), 524–538.
13. Mikolajczak, M., Pinon, N., Lane, A., de Timary, P., Luminet, O., Oxytocin not only increase trust when money is at stake, but also when confidential information is in the balance. Biol. Psychol. 85 (2010), 182–184.
14. Miller, W.R., Rollnick, S., Motivational Interviewing: Helping People Change, 3rd edition, 2013, Guilford Press, New York.
15. Nakagawa, S., Cuthill, I.C., Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol. Rev. 82 (2007), 591–605.
16. de Oliveira, D.C., Zuardi, A.W., Graeff, F.G., Queiroz, R.H., Crippa, J.A., Anxiolytic-like effect of oxytocin in the simulated public speaking test. J. Psychopharmacol. 26:4 (2012), 497–504.
17. Sarnyai, Z., Kovacs, G.L., Oxytocin in learning and addiction: from early discoveries to the present. Pharm. Biochem Behav. 119 (2014), 3–9.
18. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., et al. The mini- international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychuatry 59:Suppl 20 (1998), 22–33 Quiz 34-57.
19. Sherman, B.J., McRae-Clark, A.L., Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy 36:5 (2016), 511–535.
20. Sobell, L., Sobell, M., Timeline Follow-Back. Litten, R., Allen, J., (eds.) Measuring Alcohol Consumption, 1992, Humana Press, 41–72.
21. Stauffer, C.S., Musinipally, V., Suen, A., Lynch, K.L., Shapiro, B., Woolley, J.D., A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder. Addict. Res. Theory 24:6 (2016), 490–498.
22. Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS): 2003–2013. National Admissions to Substance Abuse Treatment Services. Substance Abuse and Mental Health Services Administration. 2014, Rockville, MD.
23. Wei, D., Lee, D., Cox, C.D., Karsten, C.A., Penagarikano, O., Geschwind, D.H., et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc. Natl. Acad. Sci. USA, 112(45), 2015 (14084-9).